Clinical validation of the Tempus xO assay
Metrics: PDF 493 views | HTML 888 views | ?
Nike Beaubier1, Robert Tell1, Robert Huether1, Martin Bontrager1, Stephen Bush1, Jerod Parsons1, Kaanan Shah1, Tim Baker1, Gene Selkov1, Tim Taxter1, Amber Thomas1, Sam Bettis1, Aly Khan1, Denise Lau1, Christina Lee1, Matthew Barber1, Marcin Cieslik2, Casey Frankenberger1, Amy Franzen1, Ali Weiner1, Gary Palmer1, Robert Lonigro2, Dan Robinson2, Yi-Mi Wu2, Xuhong Cao2, Eric Lefkofsky1, Arul Chinnaiyan2,3 and Kevin P. White1
1Tempus Labs, Inc., Chicago, Illinois 60654, USA
2Department of Pathology and Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA
3Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA
Nike Beaubier, email: firstname.lastname@example.org
Kevin P. White, email: email@example.com
Keywords: genomic test; gene panel; cancer; transcriptome; Tempus
Received: August 20, 2017 Accepted: March 21, 2018 Published: May 25, 2018
We have developed a clinically validated NGS assay that includes tumor, germline and RNA sequencing. We apply this assay to clinical specimens and cell lines, and we demonstrate a clinical sensitivity of 98.4% and positive predictive value of 100% for the clinically actionable variants measured by the assay. We also demonstrate highly accurate copy number measurements and gene rearrangement identification.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.